Hospital
Steward Rockledge Hospital, INC.
Steward Rockledge Hospital, INC. was paid $6.16M by Medicaid between Jan 2018 and Dec 2024, across 198 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 14% of everything it billed.
33Billing provider infoSTEWARD ROCKLEDGE HOSPITAL, INC.
ROCKLEDGE, FL 32955
ROCKLEDGE, FL 32955
33aNPI1437682127assigned 04/10/2017
33bProvider typePsychiatric Hospital Unit
28Total paid$6.16M
24GClaims348,356
24DCodes billed198
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Florida
Rank by total paid#10 of 15
Median peer was paid$7.13M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOYLE, JOHN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,222 | $432K | |
| 2019 | 87,888 | $1.26M | |
| 2020 | 78,901 | $1.22M | |
| 2021 | 80,903 | $1.48M | |
| 2022 | 48,769 | $1.14M | |
| 2023 | 14,267 | $472K | |
| 2024incomplete | 3,406 | $161K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 14% | 24,070 | 16,741 | $886K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 15,162 | 12,786 | $829K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 15,238 | 13,382 | $819K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 8,979 | 7,334 | $383K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 3,266 | 2,602 | $259K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 5,567 | 4,559 | $237K |
| 80053 | Comprehensive metabolic panel | 3.8% | 20,017 | 15,765 | $232K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 1,921 | 1,613 | $222K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 1,726 | 1,405 | $170K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 3,672 | 2,360 | $140K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 1,783 | 1,592 | $119K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 1,535 | 1,339 | $105K |
186 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,113 | $80K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 8,960 | $73K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 422 | $68K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,744 | $65K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 650 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,343 | $54K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 603 | $53K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 877 | $41K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 261 | $38K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,979 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,884 | $36K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 814 | $35K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,838 | $33K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 736 | $33K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,579 | $32K |
| 81001 | <1% | 8,055 | $32K | |
| 76641 | <1% | 658 | $31K | |
| 81003 | <1% | 5,255 | $27K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,686 | $27K |
| G0378 | Hospital observation service, per hour | <1% | 2,998 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,082 | $24K |
| 81025 | <1% | 4,664 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,718 | $24K |
| 73610 | <1% | 593 | $24K | |
| 82947 | <1% | 2,535 | $23K | |
| 59025 | Fetal non-stress test | <1% | 464 | $23K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,277 | $22K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,978 | $21K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 303 | $21K |
| 85610 | <1% | 5,568 | $20K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,117 | $20K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,207 | $20K |
| 93975 | <1% | 1,057 | $19K | |
| 73630 | <1% | 729 | $19K | |
| 73562 | <1% | 684 | $18K | |
| 73030 | <1% | 470 | $18K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,452 | $17K |
| 73130 | <1% | 443 | $17K | |
| 87081 | <1% | 594 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,893 | $16K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 380 | $15K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,999 | $15K |
| 82962 | <1% | 1,810 | $15K | |
| 00731 | <1% | 264 | $14K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,148 | $14K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,127 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 861 | $13K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 972 | $12K |
| 85730 | <1% | 4,030 | $12K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 210 | $12K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 473 | $12K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 526 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,078 | $11K |
| C1769 | Guide wire | <1% | 654 | $11K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 934 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,570 | $11K |
| 84484 | <1% | 6,326 | $10K | |
| 86850 | <1% | 1,351 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 165 | $9K |
| 93017 | <1% | 466 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 363 | $8K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 212 | $8K |
| 80050 | General health panel | <1% | 922 | $8K |
| 73110 | <1% | 171 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,519 | $8K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,818 | $7K |
| 87631 | <1% | 194 | $7K | |
| 83735 | <1% | 4,079 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,991 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,585 | $6K |
| 71250 | <1% | 117 | $6K | |
| 85027 | <1% | 1,716 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 174 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,902 | $6K |
| 76801 | <1% | 642 | $5K | |
| 72100 | <1% | 288 | $5K | |
| 83690 | <1% | 3,957 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 292 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,917 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,653 | $4K |
| 77066 | Tomosynthesis, mammo | <1% | 45 | $4K |
| 99153 | Mod sedat endo service >5yrs | <1% | 207 | $4K |
| 99152 | <1% | 119 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 894 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,949 | $4K |
| 86900 | <1% | 2,012 | $4K | |
| 96376 | <1% | 209 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,557 | $4K |
| 00811 | <1% | 28 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 819 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 543 | $3K |
| 87040 | <1% | 1,999 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,934 | $3K |
| 74018 | <1% | 163 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,691 | $3K |
| 83880 | <1% | 1,488 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 797 | $3K |
| 80061 | Lipid panel | <1% | 3,625 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,520 | $2K |
| 87210 | <1% | 268 | $2K | |
| 83605 | <1% | 1,739 | $2K | |
| 93971 | <1% | 111 | $2K | |
| 87186 | <1% | 1,498 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 350 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,438 | $2K |
| 84703 | <1% | 2,364 | $2K | |
| 97161 | <1% | 103 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 116 | $2K |
| 72131 | <1% | 99 | $2K | |
| 87070 | <1% | 359 | $2K | |
| 73502 | <1% | 80 | $2K | |
| 82607 | <1% | 1,057 | $1K | |
| 97597 | <1% | 21 | $1K | |
| 86901 | <1% | 2,020 | $1K | |
| 84702 | <1% | 1,353 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 545 | $1K |
| 87807 | <1% | 230 | $995.58 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 46 | $991.48 |
| 73080 | <1% | 34 | $987.13 | |
| 84600 | <1% | 858 | $921.99 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 17 | $905.92 |
| 92551 | <1% | 21 | $866.70 | |
| 85379 | <1% | 1,078 | $834.58 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 844 | $761.20 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,094 | $741.33 |
| 87088 | <1% | 902 | $683.19 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $675.90 |
| 87077 | <1% | 152 | $607.88 | |
| 82746 | <1% | 272 | $601.10 | |
| 88342 | <1% | 761 | $544.41 | |
| 82570 | <1% | 733 | $528.76 | |
| 82550 | <1% | 237 | $504.13 | |
| 85378 | <1% | 19 | $452.92 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 485 | $421.33 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 28 | $402.07 |
| 84439 | <1% | 969 | $375.95 | |
| J3490 | Unclassified drugs | <1% | 19 | $266.45 |
| 82553 | <1% | 42 | $251.10 | |
| 86140 | <1% | 374 | $177.09 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 551 | $152.76 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 110 | $140.93 |
| 80143 | <1% | 399 | $135.39 | |
| 90715 | <1% | 80 | $133.04 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 99 | $132.86 |
| 88313 | <1% | 311 | $124.44 | |
| 80179 | <1% | 302 | $90.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 283 | $88.05 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 336 | $86.94 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 60 | $73.93 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 97 | $73.93 |
| 82043 | <1% | 298 | $66.98 | |
| 87205 | <1% | 343 | $57.52 | |
| 82728 | <1% | 221 | $54.01 | |
| 87428 | <1% | 150 | $30.81 | |
| A4218 | Sterile saline or water, metered dose dispenser, 10 ml | <1% | 73 | $27.51 |
| 88307 | <1% | 32 | $24.80 | |
| 82805 | <1% | 51 | $19.49 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 89 | $19.06 |
| 80069 | <1% | 29 | $17.13 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 45 | $13.30 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 142 | $10.76 |
| 83540 | <1% | 163 | $7.38 | |
| 83550 | <1% | 129 | $6.68 | |
| 80320 | <1% | 18 | $6.68 | |
| 85014 | <1% | 64 | $4.11 | |
| 87075 | <1% | 16 | $2.69 | |
| 85520 | <1% | 18 | $2.38 | |
| 85018 | <1% | 64 | $2.05 | |
| 85651 | <1% | 183 | $2.05 | |
| 84156 | <1% | 14 | $1.48 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 77 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 220 | $0.00 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 283 | $0.00 |
| 00840 | 0% | 48 | $0.00 | |
| 84550 | 0% | 109 | $0.00 | |
| 36600 | 0% | 29 | $0.00 | |
| 00812 | 0% | 16 | $0.00 | |
| 83970 | 0% | 17 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 22 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 85 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 59 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 83 | $0.00 |
| 86403 | 0% | 28 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 54 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 17 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOYLE, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Steward ST. Annes Hospital Corporation | Fall River, MA | $82.71M |
| Steward Trumbull Memorial Hospital, INC. | Warren, OH | $16.49M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $6.76M |
| Southwest General Hospital LP | San Antonio, TX | $5.84M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $5.84M |
| SHC Youngstown Ohio Laboratory Services Company LLC | Poland, OH | $3.41M |
| Steward Melbourne Hospital, INC. | Melbourne, FL | $3.35M |
| Steward Hillside Rehabilitation Hospital, INC. | Warren, OH | $2.74M |
| Steward Sebastian River Medical Center, INC. | Sebastian, FL | $2.16M |
| Steward Northside Medical Center, INC. | Youngstown, OH | $1.58M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $974K |
| Newberry County EMS | Newberry, SC | $758K |
| Steward Sharon Regional Health System, INC. | Mercer, PA | $181K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.